Alterity Therapeutics (DB:PBN0) - Aktienkurs, Nachrichten und Analyse

PBN0 Aktienübersicht

Engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia.

Über das Unternehmen

PBN0 grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	3/6
Künftiges Wachstum	2/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	6/6
Dividenden	0/6

Belohnungen

Prognostiziertes jährliches Umsatzwachstum 76.7%

Im Vergleich zu Wettbewerbern und der Branche gut bewertet

Risikoanalyse

Die Erträge werden in den nächsten 3 Jahren voraussichtlich um durchschnittlich 19.5% pro Jahr sinken.

Aktien sind hochgradig illiquide

Hat keine nennenswerten Einnahmen (A$5M)

Hat keine nennenswerte Marktkapitalisierung (€20M)

+ 1 mehr Risiko

Alterity Therapeutics Limited Wettbewerber

co.don

XTRA:CNW

€6.5m

2invest

XTRA:2INV

€60.4m

Medigene

XTRA:MDG1

€29.5m

Heidelberg Pharma

XTRA:HPHA

€110.5m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Alterity Therapeutics
Historische Aktienkurse
Aktueller Aktienkurs	AU$3.76
52-Wochen-Hoch	AU$7.45
52-Wochen-Tief	AU$2.40
Beta	0.86
11 Monat Veränderung	0%
3 Monate Veränderung	15.27%
1 Jahr Veränderung	-47.11%
33 Jahre Veränderung	-26.95%
5 Jahre Veränderung	-75.62%
Veränderung seit IPO	-99.06%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	PBN0	DE Biotechs	DE Markt
7D	0%	1.0%	1.5%
1Y	-47.1%	-15.4%	12.6%

Rendite im Vergleich zur Industrie: PBN0 unter dem Niveau der Branche German Biotechs, die im vergangenen Jahr eine Rendite von -36.9% erzielte.

Rendite vs. Markt: PBN0 hinter dem Markt German zurück, der im vergangenen Jahr eine Rendite von 8.6 erzielte.

Preisvolatilität

Is PBN0's price volatile compared to industry and market?
PBN0 volatility
PBN0 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.3%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	11.7%
10% least volatile stocks in DE Market	2.4%

Stabiler Aktienkurs: PBN0 hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: [Unzureichende Daten]], um die Volatilitätsveränderung von PBN0 im vergangenen Jahr zu bestimmen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1997	12	David Stamler	alteritytherapeutics.com

Alterity Therapeutics Limited's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Alterity Therapeutics im Vergleich zum Marktanteil des Unternehmens?
PBN0 grundlegende Statistiken
Marktanteil	€11.93m
Gewinn(TTM)	-€8.74m
Umsatz(TTM)	€3.15m

3.8x

Kurs-Umsatz-Verhältnis

-1.4x

Kurs-Gewinn-Verhältnis

Ist PBN0 zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
PBN0 Gewinn- und Verlustrechnung (TTM)
Einnahmen	AU$5.15m
Kosten der Einnahmen	AU$318.80k
Bruttogewinn	AU$4.83m
Sonstige Ausgaben	AU$19.13m
Umsatz	-AU$14.30m

Zuletzt gemeldete Gewinne

Dec 31, 2022

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-0.0059
Bruttomarge	93.81%
Nettogewinnspanne	-277.57%
Schulden/Eigenkapital-Verhältnis	0%

Wie hat sich PBN0 auf lange Sicht entwickelt?

Historische Performance und Vergleiche

PBN0 Aktienübersicht

Belohnungen

Risikoanalyse

Alterity Therapeutics Limited Wettbewerber

XTRA:CNW

€6.5m

XTRA:2INV

€60.4m

XTRA:MDG1

€29.5m

XTRA:HPHA

€110.5m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Alterity Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.406192 million.

Alterity Therapeutics Limited Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

Alterity Therapeutics Limited Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Diseases

Alterity Therapeutics Limited has filed a Follow-on Equity Offering in the amount of $6 million.

Alterity Therapeutics's Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

Recent updates

Alterity Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.406192 million.

Alterity Therapeutics Limited Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

Alterity Therapeutics Limited Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Diseases

Alterity Therapeutics Limited has filed a Follow-on Equity Offering in the amount of $6 million.

Alterity Therapeutics's Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

Alterity Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 4.8 million.

Alterity Therapeutics Limited Announces CFO Changes

Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease

Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy

Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy

Alterity Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

Alterity Therapeutics Completes Enrolment in Ath434-201 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics Completes Enrolment in Ath434-201 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics Limited, Annual General Meeting, Nov 29, 2023

Alterity Therapeutics Limited Grants New Composition of Matter Patent in Europe for Neurodegenerative Diseases Including Parkinson's and Alzheimer's

Alterity Therapeutics Limited Announces an Independent Data Monitoring Committee Recommends the ATH434-201 Phase 2 Study

Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder

Alterity Therapeutics Enrolls First Patient in Australia in Ath434 Global Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics Limited Receives Regulatory Approval for Phase II Trial in France and Austria

Alterity Therapeutics Limited Announces A Study Recently Published in the Journal Neurotherapeutics Demonstrated Its Lead Clinical Asset, Ath34, Was Neuroprotective in A Genetic Model of Parkinson's Disease

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy

Alterity Therapeutics Limited Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy

Alterity Therapeutics Limited Announces A New Composition of Matter Patent Allowed by the United States Patent and Trademark Office

Alterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual Meeting

Alterity Therapeutics Limited, Annual General Meeting, Nov 11, 2022

Alterity Therapeutics Announces Presentation of Wearable Sensor Data from the Biomuse Natural History Study At the International Congress of Parkinson's Disease and Movement Disorders

Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe

Alterity Therapeutics Limited Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics Limited Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy

Alterity Therapeutics Limited Launches ATH434 Phase 2 Clinical Trial

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom

Alterity Therapeutics Announces Presentation of bioMUSE Data at the American Academy of Neurology (AAN) Annual Meeting

Alterity Therapeutics Announces Publication Demonstrating ATH434 Is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson’s Disease

Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson’S and Alzheimer’S

Alterity Therapeutics Limited Announces First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial

Alterity Therapeutics Announces Data Was Presented from the Company’s Biomarkers of Progression in Multiple System Atrophy Study

United States Patent and Trademark Office Issues Notice of Allowance for Patent Application of Alterity Therapeutics to Expand its Portfolio of Compounds for Neurodegenerative Diseases Including Alzheimer's and Parkinson's

Alterity Therapeutics Limited Announces New Publication Demonstrates ATH434 Is Neuroprotective

Alterity Therapeutics Limited announced that it has received AUD 17.17604 million in funding

Alterity Therapeutics Granted Anew Us Patent Targeting Major Neurodegenerative Diseases Including Alzheimer's and Parkinson's

Alterity Therapeutics Limited Received European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial

Alterity Therapeutics Limited to Report First Half, 2021 Results on Feb 25, 2021

Alterity Therapeutics Limited Appoints Dr. David Stamler as CEO

Alterity Announces Approval of US Patent for Next Generation Compounds to Treat Neurodegenerative Diseases

Alterity Therapeutics Commences Enrolling Multiple System Atrophy Patients in bioMUSE Study

Alterity Therapeutics Limited announced that it expects to receive AUD 35 million in funding

Alterity Therapeutics Limited Auditor Raises 'Going Concern' Doubt

Alterity Therapeutics Limited to Report Fiscal Year 2020 Results on Sep 09, 2020

Aktionärsrenditen

Preisvolatilität

Über das Unternehmen

Alterity Therapeutics Limited's Grundlagenzusammenfassung

3.8x

-1.4x

Erträge &amp; Einnahmen

Erträge & Einnahmen